Phase I Study of Continuous-Infusion L-S,R-Buthionine Sulfoximine With Intravenous Melphalan
| Autor: | Greg Ripple, Dona Alberti, Chriss Feierabend, Howard H. Bailey, Rhoda Z. Arzoomanian, R. Timothy Mulcahy, Kendra D. Tutsch, Julian C. Schink, George Wilding, Marcia Pomplun, David M. Mahvi |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male Melphalan Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty medicine.medical_treatment Phases of clinical research Pharmacology Drug Administration Schedule chemistry.chemical_compound In vivo Neoplasms Antineoplastic Combined Chemotherapy Protocols Humans Medicine Buthionine sulfoximine Lymphocytes Infusions Intravenous Antineoplastic Agents Alkylating Buthionine Sulfoximine Aged Chemotherapy business.industry Glutathione Middle Aged Surgery Treatment Outcome Oncology Tolerability chemistry Female business Perfusion medicine.drug |
| Zdroj: | JNCI Journal of the National Cancer Institute. 89:1789-1796 |
| ISSN: | 1460-2105 0027-8874 |
| Popis: | Background: Increased intracellular glutathione has long been associated with tumor cell resistance to various cytotoxic agents. An inhibitor of glutathione biosynthesis, L-S,R-buthionine sulfoximine (BSO), has been shown to enhance the cytotoxicity of chemotherapeutic agents in vitro and in vivo. We performed a phase I study of BSO administered with the anticancer drug melphalan to determine the combination's safety/tolerability and to determine clinically whether BSO produced the desired biochemical end point of glutathione depletion ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|